Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CHTR1D
The experimentally established mechanism targets of Ergotamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HTR6 | P50406 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergotamine SCHEMBL783018 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22171508 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL18134607 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL1483 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783017 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL453882 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29567350 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL11086376 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL28990226 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22231343 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025226786-A1 | METHODS AND COMPOSITIONS COMPRISING WETTABLE ELECTROSPUN MATRIX | POLY-MED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250289909-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12351656-B2 | Functionalized and crosslinked polymers | PMIDG, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250161539-A1 | INJECTION OF COLLAGEN ELASTIN HYDROGEL MICROPARTICLES INTO TORN TENDONS AND LIGAMENTS | PETVIVO HOLDINGS INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12303520-B2 | Aqueous nebulization composition | NEPHRON PHARMACEUTICALS CORPORATION (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250000693-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATING SUPRAPUBIC FAT | MIRAKI INNOVATION THINK TANK LLC (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024254456-A1 | POINT OF USE DEVICE COATING | PMIDG, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-118731222-A | Extraction method and detection method of ergot alkaloid mycotoxins in pasture | 呼和浩特海关技术中心 | 2024-10-01 | — | — | CN | disclosed |
| US-20240285517-A1 | Biocompatible Protein-Based Particles and Methods Thereof | PETVIVO HOLDINGS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4121169-A2 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | ReVance Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2023278891-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATING SUPRAPUBIC FAT | MIRAKI INNOVATION THINK TANK LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220296866-A1 | METHODS, DEVICES AND COMPOSITIONS FOR LOCAL DELIVERY | POLY-MED, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220288092-A1 | Aqueous Nebulization Composition | NEPHRON PHARMACEUTICALS CORPORATION (US) | 2022-09-15 | — | — | US | disclosed |
| US-11440976-B2 | Functionalized and crosslinked polymers | PMIDG, LLC (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220202703-A1 | IN SITU GEL-FORMING DELIVERY SYSTEMS, METHODS AND COMPOSITIONS | POLY-MED, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2022120097-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG, LLC (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11344562-B2 | Aqueous nebulization composition | NEPHRON PHARMACEUTICALS CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3979947-A1 | METHODS, DEVICES AND COMPOSITIONS FOR LOCAL DELIVERY | Poly-Med Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022032111-A1 | ICED-WATER SLURRY FOR TREATING BROWN AND BEIGE FAT | MIRAKI INNOVATION THINK TANK LLC (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344562-B2 | Aqueous nebulization composition | PDE12, CYP11B2, IL5 | ADRA2A 270/4885ADRA2B 81/4885ADRA2C 31/4885 |
| US-20220288092-A1 | Aqueous Nebulization Composition | PDE12, CYP11B2, IL5 | ADRA2A 270/4885ADRA2B 81/4885ADRA2C 31/4885 |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | ADRA2A 400/4885ADRA2B 846/4885ADRA2C 785/4885 |
| US-12303520-B2 | Aqueous nebulization composition | PDE12, CYP11B2, IL5 | ADRA2A 270/4885ADRA2B 81/4885ADRA2C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.